Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What is the effect of adding epinephrine to lignocaine (a local anesthetic)?

Decreases absorption of local anesthetic. ***Decreases absorption of local anesthetic*** - Epinephrine causes **vasoconstriction** at the site of injection, which reduces the rate at which the local anesthetic is absorbed into the systemic circulation. - This slower absorption leads to a **higher concentration of the anesthetic** at the nerve fibers, prolonging its effect and reducing systemic toxicity. - This is the primary mechanism by which epinephrine enhances local anesthetic efficacy. *Increases distribution of local anesthetic* - The primary effect of epinephrine is to **localize the anesthetic** by reducing its systemic distribution. - This localization is achieved through **vasoconstriction**, which keeps the drug at the desired site rather than allowing it to distribute widely. *Decreases duration of local anesthetic* - By slowing absorption, epinephrine effectively **increases the duration of action** of the local anesthetic. - The anesthetic remains at the site of action for a longer period, providing **extended pain relief**. *Increases metabolism of local anesthetic* - Epinephrine does not directly affect the **metabolic rate** of local anesthetics. - The primary mechanism of metabolism for amides like lignocaine is in the **liver** by cytochrome P450 enzymes.

Q: Which of the following is not a phase I reaction?

Conjugation. ***Conjugation*** - **Conjugation** reactions are characteristic of **phase II metabolism**, where a polar molecule is added to the drug to increase its water solubility and facilitate excretion. - This process is distinct from phase I reactions which primarily involve exposure of functional groups. *Oxidation* - **Oxidation** is a primary **phase I metabolic reaction**, often mediated by cytochrome P450 enzymes. - It introduces or exposes a polar functional group on the drug molecule. *Reduction* - **Reduction** is another key **phase I metabolic reaction**, which involves the gain of electrons by a drug molecule. - This reaction can alter the drug's activity or prepare it for further metabolism. *Hydrolysis* - **Hydrolysis** is a **phase I metabolic reaction** that involves the cleavage of a chemical bond by water. - This process typically breaks down esters and amides, exposing functional groups.

Q: Which of the following best demonstrates the variability in drug responsiveness among individuals?

Quantal Dose Response Curve. ***Quantal Dose Response Curve*** - A **quantal dose-response curve** plots the percentage of individuals exhibiting a discrete, all-or-none effect against the log dose of a drug. - This curve directly illustrates the **variability in drug responsiveness** within a population by showing the range of doses required to produce a specific effect in different individuals. *Efficacy* - **Efficacy** refers to the maximum effect a drug can produce, regardless of the dose. - While efficacy is an important pharmacological parameter, it describes the drug's overall therapeutic potential, not the **individual variability** in response. *Potency* - **Potency** is a measure of the amount of drug needed to produce an effect of given intensity. - It relates to the absolute dose required for a particular effect but does not directly demonstrate the **inter-individual differences** in biological response. *Graded Dose Response Curve* - A **graded dose-response curve** depicts the relationship between the dose of a drug and the **magnitude of the effect** in a **single biological unit** (e.g., an individual, a tissue, or a cell). - This curve reflects the relationship between drug concentration and effect intensity, but not the **variability in response among different individuals** in a population.

Q: Which of the following drugs should be given in a sustained-release oral dosage form?

An antihypertensive with a plasma half-life of 3 hours. *An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT* - An extremely short **half-life** (10 seconds) indicates a drug suitable for **rapid-onset, acute interventions**, where the effect is needed immediately and for a very brief duration, making sustained release impractical. - Drugs like **adenosine**, used for acute PSVT, are given intravenously as a rapid bolus due to their ultra-short half-life, not in an oral sustained-release form. *Anti inflammatory drugs with the plasma half life of 24 hours* - A long **half-life** (24 hours) typically means the drug can be administered **once daily** to maintain therapeutic concentrations, rendering a sustained-release formulation unnecessary. - Such drugs already provide **prolonged action** and do not benefit significantly from further extension of release. *Hypnotic drugs with a plasma half life of 2 hours* - While a 2-hour half-life for a hypnotic might suggest potential for sustained release to prolong sleep, the goal of hypnotics is often a **rapid onset and relatively short duration** to avoid hangover effects. - Sustained release might cause **daytime sedation** and interfere with normal wakefulness, which is generally undesirable for this class of drugs. ***An antihypertensive with a plasma half-life of 3 hours*** - A short **half-life** (e.g., 3 hours) often necessitates frequent dosing to maintain therapeutic levels, making a **sustained-release formulation desirable** for patient compliance and consistent drug exposure. - Sustained-release dosage forms are particularly useful for drugs requiring **long-term, stable plasma concentrations**, such as antihypertensives, to manage chronic conditions effectively.

Q: Which of the following is a metabotropic receptor?

Beta receptor for norepinephrine. ***Beta receptor for norepinephrine*** - **Beta-adrenergic receptors** (like those for norepinephrine) are **G protein-coupled receptors**, which are the hallmark of metabotropic receptors. - Activation of these receptors leads to a cascade of **intracellular signaling events** through second messengers, rather than direct ion channel opening. *GABA-A receptor* - The **GABA-A receptor** is a **ligand-gated ion channel** (ionotropic receptor) that, when activated by GABA, allows chloride ions to flow into the neuron. - This influx of **chloride ions** causes hyperpolarization, leading to an inhibitory effect. *Nicotinic acetylcholine receptor* - The **nicotinic acetylcholine receptor** is a **ligand-gated ion channel** (ionotropic receptor) that, upon binding acetylcholine, directly opens to allow the passage of sodium and potassium ions. - This ion movement causes **depolarization** and excitation of the postsynaptic cell. *NMDA receptor* - The **NMDA receptor** is a type of **glutamate receptor** that functions as a **ligand-gated ion channel** (ionotropic receptor) and is permeable to Na+, K+, and Ca2+. - Its activation requires both **glutamate binding** and depolarization to remove a magnesium block, directly leading to ion flow.

Q: Which of the following statements is true regarding competitive reversible antagonism?

Efficacy and Vmax remain unchanged.. ***Efficacy and Vmax remain unchanged.*** - In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2]. - The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor. - This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2]. *Potency remains unchanged in the presence of a competitive antagonist.* - **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3]. - A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4]. - The dose-response curve shifts to the right (parallel shift) [4]. *ED50 remains unchanged in competitive reversible antagonism.* - **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect. - Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4]. *Affinity (Kd) remains unchanged in competitive reversible antagonism.* - The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1]. - In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy. - The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.

Q: A partial agonist has:

High affinity with low intrinsic activity. ***High affinity with low intrinsic activity*** - A **partial agonist** binds to the receptor with **high affinity** [1] but elicits a submaximal response, indicating partial activation [1],[2]. - Its **intrinsic activity** is greater than zero but less than that of a full agonist [2]. *High affinity with no intrinsic activity* - This describes an **antagonist**, which binds to the receptor with **high affinity** but produces no biological effect (zero intrinsic activity). - An antagonist simply blocks the action of other agonists. *Low affinity with high intrinsic activity* - While binding affinity and intrinsic activity are distinct properties, a drug with **high intrinsic activity** typically produces a strong effect, and low affinity would mean a higher concentration is needed for that effect. This combination does not define a partial agonist. - A full agonist would have **high intrinsic activity**, but affinity can vary. *Low affinity with low intrinsic activity* - A drug with both **low affinity** and **low intrinsic activity** would be a very weak partial agonist, requiring high concentrations to produce only a small effect. - While it technically describes a type of partial agonist, the defining characteristic of a partial agonist is often highlighted by its ability to bind effectively (high affinity) but only partially activate (low intrinsic activity) a receptor.

Q: Renal threshold of a drug means:

Drug concentration above which it appears in urine. ***Drug concentration above which it appears in urine*** - The **renal threshold** refers to the plasma concentration of a substance that, when exceeded, leads to its excretion in the urine because the renal tubules' reabsorptive capacity is saturated. - For drugs, if their concentration in the blood surpasses this threshold, the kidneys are unable to reabsorb all of it, resulting in its appearance in the urine. *Drug concentration below which it appears in urine* - This statement is incorrect as it contradicts the definition of renal threshold, which implies excretion when concentrations are *high*, not low. - Substances generally do not appear in urine when their concentration is below the renal threshold because the kidneys efficiently reabsorb them. *Drug concentration above which it appears in blood* - This option is flawed because drugs are always present in the blood if administered; their appearance in the blood is not dictated by a threshold in this context. - The renal threshold specifically relates to the kidney's handling of substances and their subsequent excretion into the urine. *Drug concentration at which it starts to be metabolized* - **Metabolism** primarily occurs in the liver, not at a specific renal concentration threshold. - The phrase "renal threshold" is explicitly about kidney function and urinary excretion, not metabolic processes.

Q: A patient named Ram Prasad is admitted to Guru Teg Bahadur Hospital with a respiratory infection. Tobramycin is ordered for treatment. Given that the clearance and volume of distribution of tobramycin in him are 160 mL/min and 40 L, respectively, calculate the intravenous loading dose required to achieve a therapeutic plasma concentration of 4 mg/L.

160 mg. ***160 mg*** - The loading dose is calculated using the formula: **Loading Dose = Volume of Distribution (Vd) × Target Plasma Concentration (Cp)**. - Given Vd = 40 L and Cp = 4 mg/L, the calculation is 40 L × 4 mg/L = **160 mg**. *0.1 mg* - This value is significantly too low for a therapeutic loading dose of tobramycin and would not achieve the desired concentration. - It likely results from incorrect units or a miscalculation of the formula. *10 mg* - This dose is too low to reach the therapeutic plasma concentration of 4 mg/L given the patient's volume of distribution. - It suggests a calculation error, possibly dividing Vd by Cp instead of multiplying. *115.2 mg* - This value indicates a calculation error, as it does not correspond to the correct application of the loading dose formula. - It might arise from using an incorrect volume of distribution or target concentration, or an error in multiplication.

Question 1

What is the effect of adding epinephrine to lignocaine (a local anesthetic)?

Accepted Answer

Decreases absorption of local anesthetic

Answer

Increases distribution of local anesthetic

Answer

Decreases duration of local anesthetic

Answer

Increases metabolism of local anesthetic

Question 2

Which of the following is not a phase I reaction?

Accepted Answer

Conjugation

Answer

Oxidation

Answer

Reduction

Answer

Hydrolysis

Question 3

Which of the following best demonstrates the variability in drug responsiveness among individuals?

Accepted Answer

Quantal Dose Response Curve

Answer

Potency

Answer

Efficacy

Answer

Graded Dose Response Curve

Question 4

Drug X has an affinity for albumin, while drug Y has 150 times greater affinity. Which of the following statements is MOST accurate?

Accepted Answer

The free concentration of drug X in blood is higher, facilitating tissue distribution.

Answer

Drug X will be more available in tissues

Answer

Drug Y will be less available in tissues

Answer

Toxicity of drug Y may be influenced by multiple factors, not just its binding.

Question 5

Which of the following drugs should be given in a sustained-release oral dosage form?

Accepted Answer

An antihypertensive with a plasma half-life of 3 hours

Answer

An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT

Answer

Anti inflammatory drugs with the plasma half life of 24 hours

Answer

Hypnotic drugs with a plasma half life of 2 hours

Question 6

Which of the following is a metabotropic receptor?

Accepted Answer

Beta receptor for norepinephrine

Answer

GABA-A receptor

Answer

NMDA receptor

Answer

Nicotinic acetylcholine receptor

Question 7

Which of the following statements is true regarding competitive reversible antagonism?

Accepted Answer

Efficacy and Vmax remain unchanged.

Answer

ED50 remains unchanged in competitive reversible antagonism.

Answer

Potency remains unchanged in the presence of a competitive antagonist.

Answer

Affinity (Kd) remains unchanged in competitive reversible antagonism.

Question 8

A partial agonist has:

Accepted Answer

High affinity with low intrinsic activity

Answer

High affinity with no intrinsic activity

Answer

Low affinity with high intrinsic activity

Answer

Low affinity with low intrinsic activity

Question 9

Renal threshold of a drug means:

Accepted Answer

Drug concentration above which it appears in urine

Answer

Drug concentration below which it appears in urine

Answer

Drug concentration above which it appears in blood

Answer

Drug concentration at which it starts to be metabolized

Question 10

A patient named Ram Prasad is admitted to Guru Teg Bahadur Hospital with a respiratory infection. Tobramycin is ordered for treatment. Given that the clearance and volume of distribution of tobramycin in him are 160 mL/min and 40 L, respectively, calculate the intravenous loading dose required to achieve a therapeutic plasma concentration of 4 mg/L.

Accepted Answer

160 mg

Answer

0.1 mg

Answer

10 mg

Answer

115.2 mg

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?